- Home
- AKRO vs EVT Comparison
AKRO vs EVT Comparison
Compare AKRO & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKRO | EVT |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 1.9B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKRO | EVT |
|---|---|---|
| Price | $54.65 | $24.51 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $73.56 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 115.5K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.32% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 6.63 |
| Revenue | N/A | ★ $69,404,302.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.55 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.34 | $19.20 |
| 52 Week High | $58.40 | $25.83 |
Technical Indicators
Market Signals| Indicator | AKRO | EVT |
|---|---|---|
| Relative Strength Index (RSI) | 68.63 | 54.24 |
| Support Level | $54.30 | $24.25 |
| Resistance Level | $54.70 | $24.74 |
| Average True Range (ATR) | 0.17 | 0.28 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 71.07 | 59.54 |
Price Performance
Historical ComparisonAbout AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.